Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls
- PMID: 38012539
- DOI: 10.1111/his.15101
Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls
Abstract
Tumour protein 63 (p63) is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28, which regulates the activity of genes involved in growth and development of the ectoderm and derived tissues. p63 protein is normally expressed in the nuclei of the basal cell layer of glandular organs, including breast, in squamous epithelium and in urothelium. p63 immunohistochemical (IHC) staining has several applications in diagnostic breast pathology. It is commonly used to demonstrate myoepithelial cells at the epithelial stromal interface to differentiate benign and in situ lesions from invasive carcinoma and to characterize and classify papillary lesions including the distinction of breast intraduct papilloma from skin hidradenoma. p63 IHC is also used to identify and profile lesions showing myoepithelial cell and/or squamous differentiation, e.g. adenomyoepithelioma, salivary gland-like tumours including adenoid cystic carcinoma, and metaplastic breast carcinoma including low-grade adenosquamous carcinoma. This article reviews the applications of p63 IHC in diagnostic breast pathology and outlines a practical approach to the diagnosis and characterization of breast lesions through the identification of normal and abnormal p63 protein expression. The biology of p63, the range of available antibodies with emphasis on staining specificity and sensitivity, and pitfalls in interpretation are also discussed. The TP63 gene in humans, which shows a specific genomic structure, resulting in either TAp63 (p63) isoform or ΔNp63 (p40) isoform. As illustrated in the figure, both isoforms contain a DNA-binding domain (Orange box) and an oligomerization domain (Grey box). TAp63 contains an N-terminal transactivation (TA) domain (Green box), while ΔNp63 has an alternative terminus (Yellow box). Antibodies against conventional pan-p63 (TP63) bind to the DNA binding domain common to both isoforms (TAp63 and p40) and does not distinguish between them. Antibodies against TAp63 bind to the N-terminal TA domain, while antibodies specific to ΔNp63 (p40) bind to the alternative terminus. Each isoform has variant isotypes (α, β, γ, δ, and ε).
Keywords: application; breast pathology; immunohistochemistry; p63; pitfalls.
© 2023 The Authors. Histopathology published by John Wiley & Sons Ltd.
Similar articles
-
p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival.Virchows Arch. 2018 Mar;472(3):351-359. doi: 10.1007/s00428-018-2324-2. Epub 2018 Feb 27. Virchows Arch. 2018. PMID: 29484502
-
Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry.Virchows Arch. 2013 Sep;463(3):415-25. doi: 10.1007/s00428-013-1459-4. Epub 2013 Jul 26. Virchows Arch. 2013. PMID: 23887585
-
p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.Am J Surg Pathol. 2001 Aug;25(8):1054-60. doi: 10.1097/00000478-200108000-00010. Am J Surg Pathol. 2001. PMID: 11474290
-
Possible Usage of p63 in Bioptic Diagnostics.Klin Onkol. 2018 Winter;31(Suppl 2):27-31. doi: 10.14735/amko20182S27. Klin Onkol. 2018. PMID: 31023021 Review. English.
-
TAp63 and DeltaNp63 in cancer and epidermal development.Cell Cycle. 2007 Feb 1;6(3):274-85. doi: 10.4161/cc.6.3.3797. Epub 2007 Feb 3. Cell Cycle. 2007. PMID: 17264681 Review.
Cited by
-
Atrial fibrillation recurrence after catheter ablation is associated with RAD51 and p63 proteins.Heliyon. 2024 Jun 13;10(12):e32874. doi: 10.1016/j.heliyon.2024.e32874. eCollection 2024 Jun 30. Heliyon. 2024. PMID: 38988509 Free PMC article.
References
-
- Fisher ML, Balinth S, Mills AA. p63-related signaling at a glance. J. Cell Sci. 2020; 133; jcs228015.
-
- Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin. Cancer Res. 2002; 8; 494-501.
-
- Murray-Zmijewski F, Lane DP, Bourdon JC. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 2006; 13; 962-972.
-
- Hanker L, Karn T, Ruckhaeberle E et al. Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Res. Treat. 2010; 122; 765-775.
-
- Expression of TP63 in breast cancer - The Human Protein Atlas [Internet]. [cited 2023 Feb 28]. Available at: https://www.proteinatlas.org/ENSG00000073282-TP63/pathology/breast+cancer
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous